Abstract 15465: Effect of Sitagliptin on Left Ventricular Function in Patients With Type 2 Diabetes a Sub Analysis of the PROLOGUE Study

BackgroundsEffect of dipeptidyl peptidase 4 inhibitor on cardiac function has been issue of debate. We evaluated the effect of sitagliptin on echocardiographic systolic and diastolic parameters as well as N-terminal pro brain natriuretic peptide (NT pro-BNP) in patients with type 2 diabetes as a sub-analysis of the PROLOGUE study.MethodsIn the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, echocardiography was performed in 152 patients in the sitagliptin group and 148 patients in the conventional group at the baseline and after 12 and 24 months of treatment. In addition to the routine echocardiographic measurements, mitral annular motion velocity pattern was recorded using pulsed tissue Doppler echocardiography. Early diastolic (e’) peak velocities were measured at mitral annular septal and lateral sides and the ratio of peak early diastolic transmitral flow velocity (E) to e’ (E/e’) was calculated.ResultsThe left ventricular (LV) size and ejection fraction did not change from baseline, after 12 months and after 24 months in the sitagliptin group and the conventional group. The LV mass decreased after 12 months and after 24 months only in the sitagliptin group. In the conventional group, NT-pro BNP level increased after 12 months, and left atrial dimension, E/septal e’ as well as E/average e’ increased after 24 months.ConclusionsSitagliptin does not adversely affect the LV systolic and diastolic function. This drug may have favorable effect in reduction of LV hypertrophy and have protective impact to the impairment of LV compliance.